DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) — MannKind Corporation MNKDa company focused on developing and commercializing innovative therapeutic products for patients suffering from endocrine and rare lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will attend Lytham Partners’ Fall 2022 Investor Conference, which takes place virtually on September 28-29, 2022.
The Company’s webcast presentation will be available for viewing on Wednesday, September 28, 2022 at 9:00 am ET on the Company’s website under Events & Presentations https://investors.mannkindcorp.com/events-and-presentations. The webcast will also be archived and available for replay.
Management will participate in virtual one-on-one meetings throughout the event. To arrange a meeting with management please contact Lytham Partners at 1×1@lythampartners.com.
About MannKind Corporation
MannKind Corporation MNKD is focused on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs in people living with endocrine and rare lung diseases.
We are committed to using our formulation skills and device development expertise to reduce the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and non-tuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry powder formulations and inhalers – provide fast and convenient delivery of drugs to the deep lungs, where they can act locally or enter the systemic circulation.
With a passionate team of Mannitarians working together nationwide, our mission is to give people control of their health and the freedom to live their lives.
please visit mannkindcorp.com to learn more and keep following us LinkedIn, Facebook, Twitter or Instagram.
Company contact:
Rose Alinaya, Investor Relations
(818) 661-5000
E-mail: ir@mannkindcorp.com
